Drug Product Performance: In Vitro–In Vivo Correlation

In vitro–in vivo correlation (IVIVC) is a predictive mathematical model demonstrating the relationship between in vitro drug properties and in vivo response. IVIVC reduces costly in vivo studies, establishes meaningful dissolution specifications, and decreases regulatory burden. A meaningful IVIVC should predict Cmax and AUC within 20%, aligning with FDA guidance while ensuring batch-to-batch consistency and validating dissolution specifications based on in vivo performance.

Level A correlation represents point-to-point correlation between in vitro dissolution and in vivo absorption, justifying manufacturing and formulation changes without additional human studies. Level B uses statistical moment analysis comparing mean dissolution times but cannot justify manufacturing changes alone. Level C relates one dissolution time point to one pharmacokinetic parameter and helps develop formulations. Multiple Level C correlations link one or multiple pharmacokinetic parameters to drug quantity dissolved at different time intervals.

Dissolution rate directly influences absorption rate and plasma drug appearance. A faster dissolution rate leads to quicker drug appearance in plasma. In a study of three sustained-release aspirin products, dissolution times were linearly correlated to absorption times, indicating aspirin's rapid absorption depends on dissolution rate. This relationship demonstrates how formulations with different dissolution rates cause differences in serum drug concentration.

The main objective of developing IVIVC is establishing the dissolution test as a substitute for in vivo bioavailability studies in humans. By establishing linear relationships between in vitro dissolution and in vivo bioavailability parameters, IVIVC enables predictive modeling. This approach facilitates clinically relevant drug product specifications methods of establishment while ensuring batch-to-batch consistency and aiding in new dosage form development without repeated human testing.

The biopharmaceutic drug classification system (BCS) provides a predictive approach relating physicochemical characteristics of drug substances and products to in vivo bioavailability, particularly for immediate-release oral drug products. BCS Class I drugs meet specific criteria enabling predictive IVIVC development. This classification system helps optimize pharmaceutical product performance by connecting drug properties to expected bioavailability outcomes in clinical settings.

IVIVC applications include ensuring batch-to-batch consistency, aiding in new dosage form development, and validating dissolution specifications based on in vivo performance. Two key approaches involve establishing linear relationships between in vitro dissolution and in vivo bioavailability parameters, and modifying dissolution methodology using previous bioavailability data. These applications enable cost-effective formulation optimization while maintaining product quality and regulatory compliance.

The correlation of serum drug concentration with the percent of drug dissolved highlights the interplay between in vitro dissolution and in vivo absorption. Various formulations with different dissolution rates produce differences in serum drug concentration profiles. Understanding this relationship is pivotal in optimizing pharmaceutical product performance and ensuring efficacy in clinical settings through predictive IVIVC modeling.